 REDWOOD CITY, Calif., Sept. 16, 2021 GLOBE NEWSWIRE -- Biomea Fusion, Inc. Biomea Nasdaq: BMEA, a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, today announced that the U.S. Food and Drug Administration FDA has cleared the companys Investigational New Drug application to begin a Phase I trial of BMF-219, a selective irreversible menin inhibitor, in adult patients with relapsed or refractory acute leukemia including those with an MLLKM2TA gene rearrangement or NPM1 mutation. 